Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
A rapid video update of the 2026 Immunotherapy for the Treatment of Multiple Myeloma guideline, highlighting key recommendations across newly diagnosed multiple myeloma, toxicity management, patient education, and…
Sebastian Kobold, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, discusses the three therapeutic axes that aim to bolster the activity of T-cells in cancer treatment, including…
Sebastian Kobold, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, comments on the challenges of pre-selecting patients who are most likely to benefit from novel immunotherapies, highlighting…
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus…
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus…
A weekly guideline recap with guideline and consensus statement updates from ACS, ASCO, and ASCO/CSCO. https://www.guidelinecentral.com/guidelines/ What’s Inside: 00:00 Background 00:05 Guideline Updates
Shannon Westin, MD, FASCO, The University of Texas MD Anderson Cancer Center & GOG-F, Houston, TX, explores interim overall survival and safety data from the Phase III DUO-E…
Shannon Westin, MD, FASCO, The University of Texas MD Anderson Cancer Center & GOG-F, Houston, TX, comments on the importance of breaking down mismatch repair proficient groups into…
Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the potential role of immunotherapy in combination with chemotherapy for patients with luminal type breast cancer, highlighting the…
Trine Nøttrup, PhD, Rigshospitalet, Copenhagen, Denmark, discusses first results from the randomized Phase II ENGOT-OV56/NSGO-CTU-DOVACC (NCT05116189) trial evaluating olaparib maintenance alone, with durvalumab, or with durvalumab plus the…